Mechanism of action on the liver
Semaglutide acts on liver fibrosis through three pathways:
- Weight loss-mediated: 10–15% body weight reduction directly reduces hepatic lipid load.
- Direct hepatic action: GLP-1 receptors are expressed on liver sinusoidal endothelial cells and hepatic stellate cells. Semaglutide reduces inflammatory cytokine signalling and stellate cell activation.
- Improved insulin sensitivity: reduces hepatic de novo lipogenesis and metabolic drive for steatosis.
The contribution of direct hepatic action is supported by trial data showing histological improvement greater than weight loss alone would predict.
ESSENCE Phase 3 trial outcomes (72 weeks)
- Histological MASH resolution: 62.9% (semaglutide) vs 17% (placebo)
- One-stage fibrosis improvement: 36.8% vs 22.5%
- Elastography liver stiffness reduction: 4–7 kPa in responders
- CAP/UAP grade improvement of one full S-stage in many responders
- Safety: consistent with established semaglutide use; GI tolerability the main issue
Regulatory and guideline positioning
- FDA (Aug 2025): approved semaglutide for biopsy-confirmed MASH with F2–F3 fibrosis.
- AASLD (Nov 2025): updated guidance includes semaglutide as a therapeutic option.
- EASO 2026 guideline: positions both semaglutide and tirzepatide in MASH treatment algorithm.
- TGA: Ozempic (T2D) and Wegovy (weight management) approved. MASH-specific indication pending.
- PBS: Ozempic listed for T2D; Wegovy listing for weight management pending.
Selection of candidates
- Biopsy- or non-invasively-confirmed MASH
- F2 or F3 fibrosis stage (cirrhosis excluded from FDA-approved indication)
- Metabolic indication for semaglutide (T2D, BMI ≥30, or BMI ≥27 with comorbidity)
- Tolerance of injectable GLP-1 therapy
Non-invasive staging in primary care
Liver biopsy is rarely required in Australian practice. The MJA 2025 consensus statement endorses FIB-4 followed by elastography:
- FIB-4 from routine LFT panel
- Elastography for indeterminate FIB-4 (1.3–2.67)
- Hepatology referral for FIB-4 > 2.67 or kPa > 12
Monitoring on semaglutide therapy
- Baseline: LFTs, FIB-4, lipids, weight, HbA1c if T2D. Elastography if FIB-4 indeterminate.
- Months 3 and 6: LFTs.
- Month 12: full repeat including elastography if previously indicated.
- Baveno VII: ≥5 kPa change between measurements = clinically meaningful.
When to refer to hepatology
- FIB-4 > 2.67 or kPa > 12 at any point
- Known or suspected cirrhosis
- Suboptimal elastography response after 12 months on therapy
- Suspected drug-induced or autoimmune component
- HCC surveillance consideration
Frequently asked questions
Is semaglutide approved for MASH in Australia?
TGA approval for the MASH indication specifically is anticipated but not yet finalised. Ozempic (T2D) and Wegovy (weight management) cover most clinically eligible patients through standard channels.
What level of fibrosis improvement should I expect on semaglutide?
ESSENCE Phase 3 data: one-stage histological fibrosis improvement in 36.8% of treated patients vs 22.5% on placebo. Elastography stiffness reductions of 4–7 kPa in responders at 12 months.
Can semaglutide treat cirrhotic MASH?
The FDA approval excludes F4 (cirrhosis). Trial data in cirrhotic populations is limited. Specialist hepatology management is required for cirrhotic patients.
Is biopsy required to start semaglutide for MASH?
FDA-approved indication is biopsy-confirmed MASH. In Australian practice, non-invasive staging via FIB-4 + elastography is widely used, supported by MJA 2025 consensus. Biopsy reserved for ambiguous cases or specific clinical questions.
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.
This page is educational and not medical advice. Always discuss your GLP-1 treatment and liver monitoring with your GP.